Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSVCBD Injection in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
NCT07620314Phase 1Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in non-Hodgkin lymphoma (NHL), sponsored by Chinese PLA General Hospital. Primary endpoints: Dose Limited Toxicity at 28 days, Adverse Events and Serious Adverse Events at 24 months and 1 more. Started Jul 2026; status: recruiting.
02
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07620314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07620314.